UPDATE: Raymond James Downgrades Voyager Therapeutics (VYGR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
November 9, 2020 4:00 PM ESTCAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates.
During the third quarter, we took important steps to advance our lead programs for Parkinsons disease and Huntingtons disease with the presentation of positive long-term clinical results and the filing of an IND, respectively. Together with our partner, Neurocrine, we are currently focused on resuming enrollment in the RESTORE-1 clinical trial for Parkinsons disease pending the requested review and assessment of patient imaging data by the DSMB. For our... More
Voyager Digital Announces Assets Under Management Have Grown 20X YTD, Surpassing $100MM
November 6, 2020 2:00 AM ESTCSE: VYGROTCQB: VYGVFBorse Frankfurt: UCD2
-- Voyager Management Scheduled to Participate at the 2020 Benzinga Global FinTech Awards event on November 10th -
NEW YORK, Nov. 6, 2020 /PRNewswire/ -Â Voyager Digital Ltd. ("Voyager" or the "Company") (CSE:... More
